Criteria for Adverse Events DRESS = drug rash with eosinophilia and systemic symptoms HE = hematoxylin-eosin mCSPC = metastatic castration-sensitive prostate cancer nmCRPC = non-metastatic castration-resistant prostate cancer SAEs = severe adverse events SJS = Stevens-Johnson syndrome TEN = toxic epidermal necrolysis

Dipeptidyl peptidase 4 inhibitors (DPP-4i) are associated with an increased risk of developing bullous pemphigoid (BP) in patients with diabetes. Autoantibodies targeting epitopes on the processed BP180, 120-kDa (LAD-1), and 97-kDa (LABD97) linear immunoglobulin (Ig)A dermatosis antigens are the major autoantibodies in DPP-4i-associated BP. However, no case of mucous membrane pemphigoid (MMP) developing during treatment with DPP-4i has been reported. We report a case of MMP associated with DPP-4i.

No abstract

A prediction model was constructed to estimate the variations of DO in the reservoir and the downstream of the dam associated with the sediment flushing. Based on the investigation of the sediment flushing in case of Dashidaira dam located in Kurobegawa-river, it is assumed that DO decrease is caused by Fe(II) oxidation, which have been reduced in the bottom sediment.To estimate quantitatively the influence of accumulating duration on DO decrease, the model describing the transport and transform process of DO, Fe(II) and Fe(III) was incorporated into the onedimensional sediment movement model. The validity of the present model is verified by the comparison of predicted results with the measured ones of the sediment flushing operations carried out at the dam on 1994 and 1999.

Pharmacological regimens with multiple medications are being used in fertility treatments. Herein, we report a case of a 40‐year‐old Japanese woman who developed Stevens‐Johnson syndrome (SJS) with a severe ocular complication during fertility treatment. Despite early multimodal interventions, including methylprednisolone pulse therapy and plasma exchange, her ocular complications persisted for more than a year. The four drugs administered in this case (cabergoline, medroxyprogesterone acetate, clomiphene, and intravenous human chorionic gonadotropin) have never been reported to induce SJS. Based on this case, we suggest that obstetricians, gynecologists, and dermatologists should be aware of fertility treatment‐induced severe drug eruptions.